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| INTRODUC TI ON
Chronic hepatitis B (CHB) infection is difficult to cure due to intrahepatic persistence of the main viral replication template cccDNA and due to complex host-virus interactions. At present, it is debated not only how to achieve cure, but also which event is the best surrogate endpoint indicating cure of disease.
1 Functional cure, often reflected by HBsAg seroconversion, is the most favourable outcome that currently available treatment options can establish, but it is achieved in only a minority of patients with HBeAg-positive CHB. [2] [3] [4] [5] Therefore, sustainable disease remission remains one of the major aims in current clinical practice.
HBeAg loss induced by (peg)interferon alpha (PEG-IFN) treatment, which mainly has immunomodulating effects, occurs in approximately 30% of patients and is associated with an increased probability of HBsAg loss and a reduced incidence of liver-related complications. 4, 6, 7 In contrast, during 1 year of antiviral therapy with potent nucleo(s)tide analogues (NA), entecavir (ETV) or tenofovir (TDF), HBeAg loss is achieved in only 20% of patients and is less durable. [8] [9] [10] Although treatment guidelines suggest that NA therapy may be discontinued in non-cirrhotic patients when HBeAg loss is achieved, [11] [12] [13] clinical relapse occurs in around 50% of patients and virological relapse in over 90%. 14, 15 Consequently, the majority of patients on NA treatment require long-term or even lifelong therapy.
Long-term NA therapy may not be desired for several reasons such as high costs, potential non-adherence and side effects.
Another disadvantage is that decline in serum level of HBsAg, which is presumed to partly reflect intrahepatic functionally active cccDNA, is very slow, resulting in low rates of on-treatment HBsAg clearance. 16, 17 On the other side, long-term HBV suppression can improve both innate immunity and adaptive immunity, probably creating a window of opportunity for immunomodulatory treatment such as PEG-IFN to improve response. 18, 19 Indeed, the first studies in small patient groups reported that addition of PEG-IFN (PEG-IFN add-on strategy) in patients with completely suppressed HBV DNA by NA therapy-increased responses rates and even leads to HBsAg loss. 20, 21 Our group recently reported the results of a randomized controlled trial comparing ETV monotherapy to ETV + 24 weeks of PEG-IFN add-on. We observed higher rates of HBeAg loss and sustained off-treatment disease remission in the PEG-IFN add-on arm,
and PEG-IFN add-on led to a significantly stronger decline in serum HBsAg level. 22, 23 However, at present, it is not known whether these benefits last over time. We therefore aimed to investigate the longterm effects of the PEG-IFN add-on strategy in comparison with ETV monotherapy.
| PATIENTS AND ME THODS

| Patients
Patients were eligible for participation in this observational long-term follow-up study if they completed follow-up of a global randomized controlled trial comparing ETV + PEG-IFN add-on therapy to ETV monotherapy (ARES study), had at least one simultaneously obtained serum
HBeAg and HBV DNA result after study completion at week 96 and were not (re)treated with PEG-IFN before start of the LTFU study. The inclusion and exclusion criteria of the initial study are described elsewhere. 22 In short, patients with HBeAg-positive, anti-HBe-negative Beyond week 96 of follow-up, rates of serological response became comparable between PEG-IFN add-on and ETV monotherapy. Although in this LTFU study initial non-responders were overrepresented in the add-on arm, PEG-IFN add-on possibly leads rather to accelerated HBeAg loss than to increased long-term HBeAg loss rates.
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Chronic hepatitis B infection, Entecavir, Peginterferon add-on after at least 24 weeks of consolidation therapy. Patients without an initial response continued ETV through the end of the study (week 96). In the long-term follow-up study, all patients were followed and treated according to the protocols of the local study sites. The study was performed in accordance with the declaration of Helsinki and the Good Clinical Practice guidelines and was approved by the ethics committee of each participating centre. All subjects gave written informed consent.
| Endpoints and definitions
The primary endpoint of this LTFU study was loss of HBeAg in combination with HBV DNA level <200 IU/mL (combined response). Secondary endpoints were HBeAg loss, HBeAg seroconversion (HBeAg loss + detectable anti-HBe), reversion to HBeAg positivity after initial HBeAg loss (sustainability of response), HBV DNA negativity (below lower limit of detection), HBsAg loss ± seroconversion, HBsAg level <1000 IU/mL and <100 IU/mL, HBsAg decline of 1 log 10 or more. End of long-term follow-up was defined as the last moment at which both serum HBeAg and HBV DNA results were available. Retreatment was regarded as relapse for the assessment of off-treatment response. 
| Laboratory test procedures
| Statistical analysis
Skewed laboratory values were log-transformed prior to analy- For HBsAg-related endpoints, only patients with at least one available HBsAg level were analysed. All statistical tests were two-sided and were evaluated at the 0.05 level of significance.
Analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA). In one patient treated with ETV monotherapy who did not fulfil criteria of combined response but had achieved HBeAg loss with an HBV DNA level below 500 IU/mL, ETV was successfully discontinued (week 120).
| Virological response
At the end of follow-up, HBV DNA level was undetectable (<20 IU/ mL in most participating centres) in 33/48 (69%) add-on-treated patients vs. in 32/48 (67%) ETV monotherapy-treated patients (P = 1.00). At this visit, 38/48 (79%) add-on-treated patients and 39/48 (81%) were receiving NA treatment. In the subgroup of patients (n = 37) who continued ETV throughout the entire initial study and LTFU period, the proportions of patients with undetectable HBV DNA level were 18/19 (95%) and 16/18 (89%), for add-on vs.
ETV monotherapy, respectively. 
| HBsAg response
| D ISCUSS I ON
This study is the first to describe the long-term effects of a PEG-IFN add-on strategy for the treatment of HBeAg-positive CHB in comparison with ETV monotherapy. Although we showed earlier that response rates 24 weeks after PEG-IFN discontinuation were higher in PEG-IFN add-on-treated patients than in ETV-treated patients, we were not able to demonstrate that PEG-IFN add-on treatment has late beneficial effects over ETV monotherapy with respect to HBeAg loss or serum HBV DNA-level undetectability. However, the strong add-on-induced serum HBsAg decline was sustained through LTFU.
These findings provide valuable information in the search for the optimal use of both currently approved treatment options which is essential as long as treatment leading to higher rates of functional cure or to complete cure is not available. Strategies that combine PEG-IFN and NA therapy simultaneously for the treatment of HBeAg-positive CHB have been studied for over a decade, but no or limited clinical benefit could be demonstrated. 4, 24, 25 The observations of partially restored immune reactivation in patients on long-term NA therapy have led to the investigation of strategies in which PEG-IFN is added to NA therapy or in which NA therapy is switched to PEG-IFN.
In the OSST study, switching from long-term ETV to 48 weeks of PEG-IFN resulted in a similar rate of on-treatment HBeAg loss as in our study, which was also higher when compared to ETV continuation. 26 However, in the OSST study, in which only patients with low HBeAg level were included, follow-up data have only been Alternatively, the lack of significant benefit as observed in this LTFU study may represent the late effects of PEG-IFN add-on only and not the durability of the early effects due to the fact that more initial non-responders were included in this retrospective LTFU study, primarily in the add-on arm. Particularly, in our Chinese sites, it was common that patients who achieved treatment response did not remain in follow-up at the same site which logically leads to an overrepresentation of patients without an early treatment success.
Therefore, unfortunately, we were not able to draw a conclusion on the off-treatment sustainability of response. Results of an additional post hoc analysis, extrapolating the current percentage of response sustainability to the ARES participants who were not included in this LTFU study, indeed suggest that when all original ARES participants would have been included in the LTFU study, the response rates achieved by PEG-IFN add-on remained higher than those of ETV monotherapy even at LTFU (Supplementary Table 1 ). Furthermore, the number of patients included in this LTFU study may be too low to demonstrate a clinically significant benefit.
We observed that PEG-IFN add-on led to an HBsAg decline of at least 1 log 10 in 58% of patients, which was double the rate of ETV monotherapy-treated patients. This was stable over time, which is probably due to the fact that most patients remained on NA therapy, and it may indicate improved immune control. 23, 31 This same phenomenon has been shown earlier by our group comparing trials with combination of PEG-IFN and ETV or Lamivudine . 23 Lower endof-treatment HBsAg level is associated with sustained off-treatment response after both NA and PEG-IFN discontinuation, [32] [33] [34] but because almost all patients included in this LTFU study received treatment after the initial study, we have not been able to assess this. Future follow-up of these patients could reveal if indeed offtreatment sustainability is better in those who have achieved a low HBsAg level.
In conclusion, although early response was stronger in PEG-IFN add-on-treated patients, rates of HBeAg loss and combined response became comparable between the treatment arms beyond week 96 of follow-up. We hypothesize that PEG-IFN add-on accelerates serological response without eventually leading to higher absolute response rates than ETV on the long-term. The data we presented here provide unique insights into the long-term outcome of a PEG-IFN add-on strategy as compared to ETV monotherapy. Although no recommendation towards the exact clinical application of PEG-IFN add-on as a strategy to increase HBeAg response or virological response can be made yet, this study may serve as a lead for exploring other pretreatment and add-on durations. We additionally suggest that the PEG-IFN add-on strategy may be used in future treatment settings when low HBsAg levels or HBeAg loss would be indicated to start a novel treatment therapeutic agent.
